Epithalon: The Human Evidence Belongs to a Different Substance

01What it is

Epithalon is a synthetic tetrapeptide, four amino acids end to end, Ala-Glu-Asp-Gly, also written Epitalon, molecular weight 390.35, PubChem CID 219042. Vladimir Khavinson is the named inventor on US 6,727,227 B1, granted 27 April 2004 and assigned to the limited liability company of the Clinic of the Institute of Bioregulation and Gerontology.

Epitalon was synthesised from the amino acid composition of Epithalamin, a bovine pineal gland extract, which makes it an analogue rather than the extract itself. FDA, the United States drug regulator, states in a footnote of its briefing document that it considers epitalon and epithalamin different substances, epithalamin being a polypeptide complex extracted from animal pineal gland.

02What the trials found, and what was actually injected

Go to PubMed and pull up 14523363, Khavinson and Morozov, the 266 person paper cited whenever somebody claims this compound extends human life. The 266 is three cohorts added together rather than one trial of 266 people. Ninety four women aged 66 to 94 at a St Petersburg war veterans home were split four ways by stratification randomisation, into placebo, Thymalin, Epithalamin or both, and given 10 mg intramuscularly daily for 10 days, 100 mg per course, double blind. A separate 20, ten women and ten men, received both agents every year for six years. And 152 people at the Institute of Gerontology in Kiev were split three ways on a different schedule, 10 mg intramuscularly in five doses at two to three day intervals, 50 mg per course, repeated over three years. Both agents are animal tissue extracts, and the words Epitalon, Epithalon and Ala-Glu-Asp-Gly appear nowhere in the paper. (PMID 14523363)

The celebrated 4.1 fold mortality reduction is the separate group of 20, given both extracts every year for six years, against the St Petersburg control arm of 22. In counts rather than folds that is 4 deaths out of 20 against 18 out of 22. The Epithalamin only arm of 24 had a six year mortality of 45.8 percent, which is 11 deaths, against 81.8 percent in control. Folds are how a study this small ends up sounding like a large one.

A later Kiev Institute of Gerontology follow up, not the 152 person cohort above, is also cited in epithalon marketing, and it used epithalamin the extract too. Over three years, 39 coronary patients received regular courses of it on top of basic therapy against 40 controls on basic therapy alone. (PMID 22451889)

03What the peptide itself has been given to people for

Ivko and colleagues 2021 is the only randomised, placebo controlled study of the tetrapeptide in humans. Seventy five healthy women aged 40 to 50 working mainly night shifts were sorted by urinary 6-sulfatoxymelatonin, a melatonin breakdown product. The 35 with age appropriate levels became a non randomised reference group; the 40 with low levels were split into two arms of 20 and given, for 20 days, either a saline sublingual spray or an AEDG spray delivering 0.5 mg a day. 6-sulfatoxymelatonin rose 1.7 fold on the peptide and did not move on placebo. The publication did not specify blinding and measured no sleep outcome.

The 2002 retinitis pigmentosa paper is the only PubMed record for epithalon or epitalon carrying the Clinical Trial publication type, and its entire human result is one sentence: a positive clinical effect in 90 percent of cases, with no patient count, dose, schedule or control group in the abstract. (PMID 12195242) I found no published study giving epitalon to a human by subcutaneous injection, the route the entire community convention runs on.

04The telomere work never left the dish

A telomere caps the end of a chromosome, telomerase is the enzyme that rebuilds those caps, and hTERT is its gene.

The founding claim is a 2003 cell culture experiment from Khavinson's own group: adding Epithalon to telomerase negative human fetal fibroblasts induced hTERT expression, telomerase activity and telomere elongation. (PMID 12937682) The concentration is absent from the abstract, and I could only recover it from FDA's read of the full paper: 50 nanograms per millilitre for four days in human fetal lung fibroblasts.

A group at Brunel University London, declaring no competing interests, reproduced dose dependent telomere lengthening in normal human cells, IBR.3 fibroblasts and HMEC epithelial cells, at 1.0 micrograms per millilitre daily for three weeks. In the breast cancer lines 21NT and BT474, at 0.1 to 1.0 micrograms per millilitre daily for four days, telomeres lengthened too, but through ALT, alternative lengthening of telomeres, which the authors call cancer cell specific. (PMID 40908429)

I found no study that has measured telomere length or telomerase activity in a human being given epitalon.

05The animals, and a dose that cannot be right

Anisimov 2003 is the best powered lifespan study: 54 female outbred Swiss derived SHR mice per group, injected subcutaneously on five consecutive days every month from three months of age until natural death, 1.0 microgram per mouse, roughly 30 to 40 micrograms per kilogram. Epitalon did not change mean life span, body weight or food consumption. What moved was maximum life span, up 12.3 percent, the last 10 percent of survivors, up 13.3 percent, leukaemia, down 6.0 fold, bone marrow chromosome aberrations, and the loss of estrous function. (PMID 14501183)

The HER-2/neu tumour result that anchors the anti cancer marketing used 1 microgram per mouse, subcutaneously, five consecutive days every month from two months of age, in female FVB/N transgenics. (PMID 12209581) A Bulletin of Experimental Biology and Medicine paper from the same group, on the same mouse model, states the dose as 1 mg subcutaneously five times a week. (PMID 12459848) One thousand times the figure every companion paper prints, and the record does not resolve which one describes what was done. A reader who takes that milligram at face value and scales it by body weight lands three orders of magnitude away from anything ever given an animal.

06How it compares

The last column is the gap between what is sold and what was measured. Epithalon's version of that gap is the narrowest and the easiest to walk past, because the substance next door is one letter away in print and the trial that belongs to it is a good one.

07Where the 10 mg came from

Two protocols circulate, both subcutaneous, under the skin. The one usually called the Russian protocol is 10 mg per day for 10 consecutive days, 100 mg per course, and the Ukrainian one is 10 mg on days 1, 5, 9, 13 and 17, 50 mg per course, both typically run one to two times a year with 4 to 6 month breaks. peptides.org attributes both to the International Peptide Society.

Trace them and they land back on the 2003 extract paper. Its St Petersburg cohort gave 10 mg intramuscularly daily for 10 days, 100 mg per course, which is the Russian protocol digit for digit, and its Kiev cohort gave 10 mg intramuscularly in five doses, 50 mg per course, which is the Ukrainian one. The paper spaces those five doses two to three days apart where the circulating protocol spaces them four. I found no vendor or clinic page that derives the 10 mg figure from any study of the tetrapeptide.

08What the regulators have on file

I could not find this compound on ClinicalTrials.gov, the United States government's registry of trials, by term or intervention. No approved epitalon product exists in any market FDA checked, and no European Medicines Agency authorisation.

FDA has also written to a compounding pharmacy, the kind that mixes drugs to order. Warning letter 594743, issued to Tailor Made Compounding LLC of Nicholasville, Kentucky on 1 April 2020, names Epitalon among the bulk drug substances the firm had compounded with, and the reason it gives is the three part test in section 503A: no applicable USP or NF monograph, not a component of an FDA approved human drug, not on the 503A bulks list. What the letter settles is one pharmacy's eligibility for a statutory exemption, not whether the peptide is safe or whether it does anything, and it is not an action against the compound itself or against anybody else selling it.

09What could go wrong

FDA raises the mechanism as a hazard: continuous lifelong exposure to something that lengthens telomeres could let cells evade senescence, the shutdown that stops an old cell dividing, and turn cancerous.

FDA identified no repeat dose toxicity study and no two year carcinogenicity study in any form, noted that the monthly schedule in the Anisimov work exposed those mice for about 5.5 months at most, and concluded there are no clinical data supporting human safety, singling out the subcutaneous route for immunogenicity risk from aggregation and impurities. Immunogenicity there means an immune reaction to the injected material.

10What nobody knows

Whether any of it even gets in. I found no pharmacokinetic study of epitalon in any species, nothing on how long a dose lasts or whether the intact tetrapeptide survives delivery under the tongue or under the skin.

Whether it helps anybody sleep. The indication FDA formally evaluated was insomnia, and it found no publication on efficacy in insomnia patients. My own search found none either.

11My take

Khavinson and Morozov were straight about what they gave people. What went wrong went wrong downstream, where a name shifted by one letter and the mortality table came with it. Take that away and what is left is 20 women on a sublingual spray, a one sentence eye result with no patient count, telomere lengthening in dishes, and a mouse study where mean life span did not move across 54 animals a group.

The cell work is the part I would not dismiss. Brunel had no stake in the result and got it anyway. But that same lab watched the peptide drive ALT in two breast cancer lines, FDA reads the whole telomerase story as a cancer concern, and FDA found no two year carcinogenicity study to settle it. I have not found a single telomere measurement in a person who took this.

If you have bought epithalon, what did the seller cite for the 10 mg figure? I would like to see one page that names a study of the tetrapeptide.

Frequently asked

Does epithalon extend human lifespan?+

The study behind that claim is real and it did not use epithalon. Khavinson and Morozov reported on 266 older patients pooled across three cohorts, and the arm given Epithalamin alone, 24 people, had a six year mortality of 45.8 percent against 81.8 percent in a control arm of 22.

Is epithalon the same thing as epithalamin?+

No. Epithalamin is a polypeptide complex extracted from animal pineal gland, and epithalon is a synthetic chain of four amino acids designed from the amino acid composition of that extract.

Does epithalon lengthen telomeres?+

In cells it does, and that has now been reproduced by a group declaring no competing interests. I found no study that has measured telomere length or telomerase activity in a human being given epitalon.

Has epithalon been given to people in a proper trial?+

FDA's literature search found exactly three, all small: two sprays under the tongue in night shift workers and one injection into the tissue around the eyeball. I found no published study giving it by injection under the skin, the route the community convention runs on.

Where does the 10 mg epithalon protocol come from?+

It is convention and marketing practice rather than a finding. I found no vendor or clinic page that derives the number from any study of the tetrapeptide.

Is epithalon safe?+

The published record does not support an answer either way. FDA identified no repeat dose toxicity study and no two year carcinogenicity study of epitalon in any form, and concluded there are no clinical data supporting human safety, singling out the injection route under the skin for immunogenicity risk.

---

This content is for educational and informational purposes only and is not medical advice. Peptides discussed are research compounds and may not be approved for human use. Nothing here should be used to diagnose, treat, cure, or prevent any disease. Always consult a qualified healthcare professional before starting any peptide, supplement, or protocol. Individual responses vary. Do not self-administer compounds without proper medical supervision.